After losing significant ground to rival Eli Lilly in the GLP-1 space over the past two years, Novo Nordisk is defending the one arena it now dominates — oral therapeutics. But with Lilly preparing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results